338 related articles for article (PubMed ID: 32975237)
1.
Saxena A; Mukhopadhyay AK; Nandi SP
J Biosci; 2020; 45(1):. PubMed ID: 32975237
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.
Oh B; Kim BS; Kim JW; Kim JS; Koh SJ; Kim BG; Lee KL; Chun J
Helicobacter; 2016 Jun; 21(3):165-74. PubMed ID: 26395781
[TBL] [Abstract][Full Text] [Related]
3. Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
Grgov S; Tasić T; Radovanović-Dinić B; Benedeto-Stojanov D
Vojnosanit Pregl; 2016 Nov; 73(11):1044-9. PubMed ID: 29328644
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Hsu PI; Pan CY; Kao JY; Tsay FW; Peng NJ; Kao SS; Wang HM; Tsai TJ; Wu DC; Chen CL; Tsai KW;
Helicobacter; 2018 Aug; 23(4):e12498. PubMed ID: 29897654
[TBL] [Abstract][Full Text] [Related]
5. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Liou JM; Chen CC; Chang CM; Fang YJ; Bair MJ; Chen PY; Chang CY; Hsu YC; Chen MJ; Chen CC; Lee JY; Yang TH; Luo JC; Chen CY; Hsu WF; Chen YN; Wu JY; Lin JT; Lu TP; Chuang EY; El-Omar EM; Wu MS;
Lancet Infect Dis; 2019 Oct; 19(10):1109-1120. PubMed ID: 31559966
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
[TBL] [Abstract][Full Text] [Related]
7. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
[TBL] [Abstract][Full Text] [Related]
8. Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial.
Kakiuchi T; Mizoe A; Yamamoto K; Imamura I; Hashiguchi K; Kawakubo H; Yamaguchi D; Fujioka Y; Nakayama A; Okuda M; Matsuo M
Helicobacter; 2020 Jun; 25(3):e12690. PubMed ID: 32207209
[TBL] [Abstract][Full Text] [Related]
9. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
10. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Zhou Y; Ye Z; Lu J; Miao S; Lu X; Sun H; Wu J; Wang Y; Huang Y
Helicobacter; 2020 Oct; 25(5):e12721. PubMed ID: 32656891
[TBL] [Abstract][Full Text] [Related]
11. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
14. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
[TBL] [Abstract][Full Text] [Related]
15. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Ahuja V; Dhar A; Bal C; Sharma MP
Aliment Pharmacol Ther; 1998 Jun; 12(6):551-5. PubMed ID: 9678815
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
Ergül B; Doğan Z; Sarikaya M; Filik L
Helicobacter; 2013 Dec; 18(6):454-8. PubMed ID: 24011287
[TBL] [Abstract][Full Text] [Related]
17. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
18. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
[TBL] [Abstract][Full Text] [Related]
19. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]